| John J Zecherle, MD | |
|
250 Bon Air Rd, Greenbrae, CA 94904-1702 | |
| (415) 925-7000 | |
| Not Available |
| Full Name | John J Zecherle |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 250 Bon Air Rd, Greenbrae, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598787871 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G49316 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Mobile Aspects, Inc., the healthcare industry's leading provider of clinical process improvement systems, today announced that it has been certified under the ISO 9001:2008 Quality Standard. Originally certified in 2008 under ISO 9001:2000 standards, this updated certification demonstrates the organization's continued commitment to maintain the highest levels of quality and customer support.
New research from The University of Texas Medical Branch at Galveston indicates that diabetic patients who got their primary care from nurse practitioners did not have an increase in potentially preventable hospital admissions.
› Verified 6 days ago
| Entity Name | Golden Gate Urgent Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073883179 PECOS PAC ID: 0648247866 Enrollment ID: O20040915001152 |
News Archive
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Mobile Aspects, Inc., the healthcare industry's leading provider of clinical process improvement systems, today announced that it has been certified under the ISO 9001:2008 Quality Standard. Originally certified in 2008 under ISO 9001:2000 standards, this updated certification demonstrates the organization's continued commitment to maintain the highest levels of quality and customer support.
New research from The University of Texas Medical Branch at Galveston indicates that diabetic patients who got their primary care from nurse practitioners did not have an increase in potentially preventable hospital admissions.
› Verified 6 days ago
| Entity Name | Petaluma Emergency Physicians Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649201898 PECOS PAC ID: 2365478914 Enrollment ID: O20050714000510 |
News Archive
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Mobile Aspects, Inc., the healthcare industry's leading provider of clinical process improvement systems, today announced that it has been certified under the ISO 9001:2008 Quality Standard. Originally certified in 2008 under ISO 9001:2000 standards, this updated certification demonstrates the organization's continued commitment to maintain the highest levels of quality and customer support.
New research from The University of Texas Medical Branch at Galveston indicates that diabetic patients who got their primary care from nurse practitioners did not have an increase in potentially preventable hospital admissions.
› Verified 6 days ago
| Entity Name | California Emergency Physicians Medical Group A Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215365218 PECOS PAC ID: 3274763875 Enrollment ID: O20140227000392 |
News Archive
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Mobile Aspects, Inc., the healthcare industry's leading provider of clinical process improvement systems, today announced that it has been certified under the ISO 9001:2008 Quality Standard. Originally certified in 2008 under ISO 9001:2000 standards, this updated certification demonstrates the organization's continued commitment to maintain the highest levels of quality and customer support.
New research from The University of Texas Medical Branch at Galveston indicates that diabetic patients who got their primary care from nurse practitioners did not have an increase in potentially preventable hospital admissions.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John J Zecherle, MD 2100 Powell St, Suite 900, Emeryville, CA 94608-1826 Ph: (510) 350-2600 | John J Zecherle, MD 250 Bon Air Rd, Greenbrae, CA 94904-1702 Ph: (415) 925-7000 |
News Archive
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Mobile Aspects, Inc., the healthcare industry's leading provider of clinical process improvement systems, today announced that it has been certified under the ISO 9001:2008 Quality Standard. Originally certified in 2008 under ISO 9001:2000 standards, this updated certification demonstrates the organization's continued commitment to maintain the highest levels of quality and customer support.
New research from The University of Texas Medical Branch at Galveston indicates that diabetic patients who got their primary care from nurse practitioners did not have an increase in potentially preventable hospital admissions.
› Verified 6 days ago
Arthur C Cohn, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 | |
Jeffrey D Weitzman, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 | |
Tami Lee Gash-kim, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 | |
Dr. William Lockwood Teufel, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 250 Bon Air Rd, Box 8010, Greenbrae, CA 94904 Phone: 415-925-7200 Fax: 415-925-7219 | |
Alan J Spain, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 | |
Lara K Kulchycki, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 | |
Andrew E Solomon, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Bon Air Rd, Greenbrae, CA 94904 Phone: 415-925-7000 |